PRTN3 and rheumatoid arthritis: Among 60 RA patients from the combined Cohort-1 and Cohort-3, multivariate logistic regression analysis identified anti-TROVE2 antibody to be an independent biomarker associated with ADAb development (odds ratio (OR) 70.27, 95% confidence interval (CI) 8.17-604.38, p < 0.001) after adjusting for age, sex, disease duration, radiographic stage, baseline DAS28, and the positivity of RF or ACPA.